National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 4) (PB 41 of 2015)

Overview

The National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 4) (PB 41 of 2015) amends the National Health Act 1953 to update the conditions under which payments will be made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. This legislative instrument was introduced to address the need to reflect changes made by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 4), which commenced on 1 May 2015. The amendment is made under the authority of paragraph 98C(1)(b) of the National Health Act 1953, which allows the Minister to determine these conditions. The primary objective of this Amendment Determination is to ensure that the Pharmaceutical Benefits Scheme remains current and reflective of the latest evidence-based recommendations from the Pharmaceutical Benefits Advisory Committee. This committee, which comprises representatives from various health sectors, ensures that the decisions regarding subsidised access to medicines are evidence-based, thereby advancing the protection of human rights by facilitating access to affordable and reliable healthcare.

Scope and Application

The National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 4) (PB 41 of 2015) amends the National Health Determination under paragraph 98C(1)(b) of the National Health Act 1953 (the Act). This amendment affects the conditions subject to which payments are made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners under the Pharmaceutical Benefits Scheme (PBS). The changes are effective from 1 May 2015 and involve the addition of a specific formulation of leuprorelin as a listed drug and the removal of a particular form of oestradiol from the list. These modifications to the Principal Determination ensure that the scheme remains aligned with the current legislative requirements and reflects the latest decisions made by the Pharmaceutical Benefits Advisory Committee. The Act applies to all entities and individuals involved in the supply of pharmaceutical benefits under the PBS, thereby ensuring that the conditions governing payments are updated in accordance with legislative changes and recommendations from relevant advisory bodies.

Key Provisions

The primary operative sections of this legislation (paragraph 98C(1)(b) of the National Health Act 1953) provide the framework under which the Minister can determine the conditions for Commonwealth payments related to the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. This Amendment Determination specifically modifies the Principal Determination (PB 119 of 2008) to incorporate changes resulting from the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 4), which came into effect on 1 May 2015. The determination adds leuprorelin in the form I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe to Schedule 4 and removes oestradiol in the form vaginal tablets 25 micrograms from the same schedule. This amendment reflects the evolving needs and availability of pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS). The Act imposes several obligations on parties involved in the supply of pharmaceutical benefits. Approved pharmacists and approved medical practitioners must comply with the conditions set out in the determination to be eligible for Commonwealth payments. These conditions include adherence to the specifications of listed drugs, ensuring that the supply of pharmaceutical benefits aligns with the provisions of the National Health Act 1953 and any subsequent amendments. The Pharmaceutical Benefits Advisory Committee (PBAC) plays a crucial role in advising the Minister on which medicines should be subsidised through the PBS, ensuring that decisions are evidence-based and consider various stakeholder interests. Breaches of the conditions set out in this determination may result in various consequences. While the legislation does not explicitly list offences or penalties, non-compliance with the conditions for Commonwealth payments could potentially lead to the denial of payments or other administrative actions by the Commonwealth. For example, if an approved pharmacist or approved medical practitioner does not adhere to the specified conditions, they may not be eligible for payments for the pharmaceutical benefits they supply. Furthermore, any significant deviations from the requirements may be subject to review and potential revocation of approval to supply pharmaceutical benefits, impacting the practitioner's ability to participate in the PBS. The human rights implications of this legislative instrument are considered in light of Articles 2 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR). By facilitating access to subsidised medicines through the PBS, the legislation supports the progressive realisation of the right to the highest attainable standard of physical and mental health. The involvement of the PBAC in the decision-making process ensures that access to medicines on the PBS is based on evidence and considers various interests, thereby advancing the protection of human rights. This legislative instrument is thus compatible with human rights as it contributes to the advancement of these rights by providing affordable access to essential medicines.